anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to recombinant Glut1 adeno-associated viral vector (rAAV) constructs and related methods for restoring Glut1 expression in Glut1 deficient mammals. In certain embodiments, the rAAV further comprises a chicken ß-actin promoter wherein the rAAV is capable of crossing the blood-brain barrier (BBB). In certain embodiments, the present invention relates to a composition comprising any of the recombinant AAV's described herein. In certain embodiments, the present invention relates to a kit comprising a container housing comprising the composition described herein. In certain embodiments, the present invention relates to methods of restoring Glut1 transport in the BBB of a subject, comprising administering to the subject an effective amount of any of the recombinant AAV vectors described herein. In certain embodiments, the present invention relates to a method of treating Glut1 deficiency syndrome in a subject in need thereof.
A colloidal facial mask with a partial carrier is revealed. The colloidal facial mask includes a colloidal layer and a carrier layer. The colloidal layer is made from colloidal film materials with high water absorption and having a first surface attached to user's face and a second surface opposite to the first surface. The carrier layer is attached and connected to at least one partial area of the second surface of the colloidal layer so as to increase mechanical strength thereof. The partial area can be an eye part, a nose part, or a mouse part. There is a partial area of the second surface of the colloidal layer not covered by the carrier layer so that the cost of the carrier layer is reduced. Moreover, the carrier layer can be preset with patterns or markers according to user's needs.
Provided herein is a gene therapy for BAG3 (B-cell Lymphoma 2–Associated Anthanogene 3),  e.g.,  using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter, a cardiac troponin T (hTNNT2) promoter, a heat shock protein 70 (HSP70) promoter, or a ubiquitin C (UBC) promoter. The capsid may be an AAVrh.74 or AAV9 capsid or a functional variant thereof. In certain embodiments, the capsid is an AAVrh.74 capsid or functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the AAV vector, and other compositions and methods.
The study was outlined to develop and approve a nomogram and chance stratification demonstrate for foreseeing overall survival of Chinese patients with at first metastatic small-cell lung cancer (SCLC). We collected information from the Surveillance, Epidemiology, and End Results (SEER) database approximately Chinese SCLC patients with at first distant metastases between 2010 and 2015. Patients with incomplete data about the follow-up time or clinicopathological information were excluded. The included patients were randomized into the training and validation set. Univariate and multivariate Cox proportional hazard regression models were performed. By integrating the significant variables screened, a prescient nomogram and risk stratification model were developed. In addition, we collected 198 small-cell lung cancer patients with metastasis at diagnosis from the case database of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine as an external validation cohort. In all, 421 patients were screened from the SEER database. Multivariate examination showed that age (P = .049), sex (P = .001), grade (P = .008), chemotherapy (P = .001), liver metastasis (P = .001), and pleural invasion (P = .012) were independent prognostic factors. The C-indicator of the nomogram to anticipate overall survival was higher than that of the eighth edition of the American Joint Committee on Cancer Tumor Node Metastasis classification system (0.75 vs 0.543; P < .001). A risk stratification model was encouraged to be created to precisely classify patients into 2 prognostic bunches. The survival rates anticipated by the nomogram appeared to have critical qualifications from the Kaplan-Meier curves in the entire SEER cohort. Calibration curves and survival predictions also showed strong accuracy and consistency in the external validation cohort. The nomogram provided a clear prognostic superiority over the traditional Tumor Node Metastasis system. It could help clinicians make individual risk predictions for initially metastatic Chinese SCLC cancer patients and give necessary treatment recommendations.
Arthritis, a prevalent inflammatory condition, is often linked to obesity as a contributing factor. This study aimed to assess the potential protective effects of purslane extract in male albino rats with induced arthritis and obesity. Fifty rats were randomly assigned to five groups: a control group, an induced arthritis-high-fat diet group, a high-dose purslane extract-supplemented group (300 mg/kg body weight) for 8 weeks, a low-dose purslane extract-supplemented group (150 mg/kg body weight) for 8 weeks, and a metformin-supplemented group. Arthritis was induced in the rats using Complete Freund's Adjuvant. Plasma biomarkers, including Total Cholesterol, Triglycerides, HDL-cholesterol, LDL-cholesterol, C Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Rheumatoid Factor (RF), and Anti-CCP, were assessed in each group. The results revealed a significant improvement in these biomarkers in the high-dose purslane-supplemented group (300 mg/kg body weight) compared to the induced arthritis-high-fat-diet group. This suggests a potential protective role of purslane against arthritis associated with obesity, likely attributed to its lipolytic capacity and anti-inflammatory properties. These findings contribute to our understanding of the interplay between obesity, arthritis, and natural interventions, providing valuable insights for future therapeutic approaches.
Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. farnesyl protein transferase).  Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.
Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
The study intervention will consist in applying HPV genotyping as a triage method of HPV-positive women for cervical cancer screening. After primary screening with the Xpert HPV test, positive women will be sorted according to two groups of genotypes: group 1 (HPV types 16,18,45, 31, 33, 35, 52 and/or 58 obtained from channels 1, 2 and 3) and group 2 (HPV types 51, 59, 39,56, 66 and/or 68 obtained from channels 4 and 5). Women of group 1 will immediately treated, while those of group 2 will not receive immediate treatment and will be followed-up at 12 months. An exception will be made for participants with lesions suspicious of invasive cancer upon examination, which will be referred for further investigations regardless of the HPV type.
PURPOSE:To obtain a proper ordered quantity by predicting future consumption from past actual result consumption, and predicting the future volume of inventories and finding the ordered quantity on the basis of the volume of inventories. CONSTITUTION:The future consumption is found by totalizing the past consumption, the predicted volume of inventories at a future next-time ordering point of time is calculated from the volume of inventories, delivery quantity, nondelivery quantity, predicted consumption, and breakage correction value at the time of last ordering, and the ordered quantity is calculated on the basis of the predicted volume of inventories which is calculated. For example, the consumption of chemicals is extracted from a data base for receipts (11), a file is given information to be distributed, and the consumption is automatically distributed according to the information (12). How many weeks the consumption is averaged for can be registered in an ordering parameter file by chemicals. The predicted consumption is calculated by multiplying the daily mean predicted consumption by the number of days up to a next ordering day (13). The proper future volume of inventories is calculated from the predicted consumption and the current ordering quantity is determined according to the calculated volume of inventories (14).
CVVHDF will be performed using Regiocit solution in the predilution mode, Biphozyl in the dialysate and postdilution mode. CRRT will be started at a dose of 35 ml/kg/h.
Veltassa is a powder for suspension in water for oral administration. The active ingredient is patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium.

The chemical name for patiromer sorbitex calcium is cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene, combination with D-glucitol. 

Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads. Patiromer sorbitex calcium is insoluble in solvents such as water, 0.1 M HCl, n-heptane and methanol. The chemical structure of patiromer sorbitex calcium is presented in Figure 1.

Figure 1: Chemical Structure of Patiromer Sorbitex Calcium

Each packet of Veltassa contains 1 gram, 8.4 grams, 16.8 grams or 25.2 grams of patiromer, the active moiety. The inactive ingredient is xanthan gum.
FIELD: medicine. ^ SUBSTANCE: invention relates to field of pharmacy, in particular to phytotherapy, and can be applied for treatment of drug hepatitis. Medication represents herbal mixture, including 29 herbs: herbal part of woodland strawberry, herbal part of common dandelion, inflorescences of pineapple weed, leaves of stinging nettle, inflorescences of tansy, inflorescences of pot marigold, fruits of common juniper, peppermint leaves, herbal part of St John's wort. Medication additionally contains: lime tree flowers, herbal part of heartsease, herbal part of Centaurium, flax seeds, dill seeds, burdock root, herbal part of common chicory, herbal part of common knotgrass, collective fruits of common hop, herbal part of cornflower, leaves of cowberries, leaves of Arctostaphylus, corn stigma, herbal part of immortelle, root and rhizome of Acorus, herbal part of Menyanthes, garden angelica root, herbal part of yellow sweet clover, Inula root, herbal part of common horsetail. ^ EFFECT: mixture reduces terms of hepatitis treatment, as well as improves clinico-laboratory indices due to normalisation of liver function tests and functional state of liver. ^ 4 ex, 2 tbl
<P>PROBLEM TO BE SOLVED: To provide a cosmetic which gives a more excellent sense of use, a more excellent sense of moisture retention, and a more excellent tomorrow practical sense of skin than those in conventional cosmetics, and has more excellent stability with the passage of days than those of the conventional cosmetics.  <P>SOLUTION: This cosmetic is characterized by containing lecithin as a component (a) and a solid fat extracted from vegetable seeds as a component (b). A higher alcohol may further be contained as a component (c). The component (a) is preferably one or more selected from the group consisting of soybean lecithin, yolk lecithin, their hydrogenated products, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl glycerol, phosphatidyl inositol, and sphingophospholipid. The component (b) is desirably Theobroma Grandiflorum Seed Butter and/or Astrocaryum Murumuru Butter.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A medical implant useful in the regeneration of soft and hard connective tissue, such as cartilage and bone, which comprises a copolymer of a major amount of epsilon caprolactone and a minor amount of lactide. Where regeneration of bone tissue, in particular, is desired, the copolymer may further include osteogenic material in powdered or particulate form. If soft tissue regeneration is desired, the copolymer may include chopped carbon fiber. A mass of the copolymer, optionally including additives, may be molded by hand by heating the polymer to a temperature of 115-160?oF, by, for example, immersion in hot water. The mass is then molded to the void to be filled or shape the regenerated tissue is desired to assume, and implanted in the patient. The mass is gradually replaced by regenerated tissue.
The invention provides a traditional Chinese medicine composition for treating a canine parvovirus disease, and belongs to the field of traditional Chinese medicines. The composition is prepared from the following components in parts by weight: 35-45 parts of ash bark, 5-15 parts of radix sophorae flavescentis, 25-35 parts of charcoal reed rhizome and 5-15 parts of selfheal. The composition takes heat-clearing, diuresis-inducing, toxicity-removing and stagnation-eliminating as the treatment principle, is reasonable in formula, simple in preparation process and wide in application range. The traditional Chinese medicine composition is prepared from pure traditional Chinese herbal medicinal materials, has the advantages of wide source, low cost, high cure rate, no drug residue and no toxic or side effect, is capable of furthest destroying plant cell walls especially after superfine grinding so as to solve the problems of high crude fiber content and insoluble effective ingredient, and can be easily absorbed by canine. The traditional Chinese medicine composition has remarkable effects of inducing diuresis, stopping bleeding, warming and nourishing stomach and intestines and regulating body functions, is capable of effectively treating canine parvovirus disease and shortening the recovery phase, and is convenient to use. Clinical tests prove that the traditional Chinese medicine composition has a cure rate of over 90 percent and has a unique curative effect.
BACKGROUND: It has been suggested that hypertrophy of the radial tuberosity may result in impingement leading to either a lesion of the distal biceps tendon or rotational impairment. Two previous studies on hypertrophy of the radial tuberosity had contradictory results and did not examine the distance between the radius and ulna: the radioulnar window. Therefore, this comparative cohort study aimed to investigate the radioulnar window in healthy subjects and compare it with that in subjects with either nontraumatic-onset rotational impairment of the forearm or nontraumatic-onset distal biceps tendon ruptures with rotational impairment of the forearm by use of dynamic 3-dimensional computed tomography measurements to attain a comprehensive understanding of the underlying etiology of distal biceps tendon ruptures. We hypothesized that a smaller radioulnar window would increase the risk of having a nontraumatic-onset distal biceps tendon rupture and/or rotational impairment compared with healthy individuals.
METHODS: This study measured the distance between the radius and ulna at the level of the radial tuberosity using entire-forearm computed tomography scans of 15 patients at the Amphia Hospital between 2019 and 2022. Measurements of healthy subjects were compared with those of subjects who had nontraumatic-onset rotational impairment of the forearm and subjects who had a nontraumatic-onset distal biceps tendon rupture with rotational impairment of the forearm. The Wilcoxon signed rank test was used for individual comparisons, and the Mann-Whitney U test was used for group comparisons.
RESULTS: A significant difference was found between the radioulnar window in the forearms of the subjects with a distal biceps tendon rupture (mean, 1.6 mm; standard deviation 0.2 mm) and the radioulnar window in the forearms of the healthy subjects (mean, 4.8 mm; standard deviation, 1.4 mm; P = .018). A trend toward smaller radioulnar windows in the rotational impairment groups was also observed, although it was not significant (P > .05).
CONCLUSIONS: The radioulnar window in the forearms of the subjects with a distal biceps tendon rupture with rotational impairment was significantly smaller than that in the forearms of the healthy subjects. Therefore, patients with a smaller radioulnar window have a higher risk of rupturing the distal biceps tendon. Nontraumatic-onset rotational impairment of the forearm may also be caused by a similar mechanism. Future studies are needed to further evaluate these findings.
Background: This study explores among individuals with a major depressive episode (MDE) the potential impact of mixed features on the risk of suicide attempt, suicidal thoughts, self-harm intentions, and thoughts of death. Methods: Data from the French Mental Health in General Population (MHGP) survey (1999-2003) were analyzed, including 128 participants meeting DSM 5 criteria for MDE with mixed features (MDE with at least 3 manic symptoms) and 3,312 participants experiencing MDE without mixed features. Our primary analysis focused on suicide attempt, with additional examination of recent suicidal thoughts, self-harm intentions, and thoughts of death. Multivariable regression models were performed to adjust for potential confounding variables, including sociodemographics, previous suicide attempt, number of depressive symptoms, and psychiatric comorbidity. Results: MDE with mixed features was significantly associated with an increased risk of suicide attempt (adjusted odds ratio [AOR] = 1.69; 95% CI, 1.26-2.25). This association did not significantly differ between men and women. Furthermore, the number of manic symptoms demonstrated a dose-dependent relationship with an increased risk of suicide attempt (AOR = 1.18; 95% CI, 1.07-1.30; P < .001). Mixed features were also associated with suicide attempt among individuals with MDE and without recent suicidal thoughts (AOR = 2.74; 95% CI, 1.36-5.54). Conclusion: This study underscores the importance of assessing mixed features when evaluating the risk of suicide attempt in individuals with MDE. Mechanisms underlying this association might be independent of progression from thoughts of death to suicidal thoughts, suicidal intention, and ultimately, suicide attempt.
The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
Despite the notion that human CD8 +  T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA- A3 -restricted epitopes recognized by circulating naive CD8 +  T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.
PURPOSE:To provide the above element which is high in mechanical strength and is usable in arbitrary forms and to increase the response speed thereof by consisting the element of the hydrous polymer gel fiber of a blend system consisting of a polyvinyl alcohol (PVA) polymer and a high-polymer electrolyte. CONSTITUTION:This element is formed to consist of the hydrous polymer gel fiber of the blend system consisting of the PVA polymer and the high-polymer electrolyte. The hydrous fiber obtd. by spinning the PVA polymer and the aq. original liquid of the high-polymer electrolyte is subjected to a freezing treatment and thawing treatment. The hydrous fiber obtd. by spinning the PVA polymer and the aq. original liquid of the high-polymer electrolyte is subjected to the freezing treatment and thawing treatment then to a neutralization treatment. The hydrous fiber obtd. by freeze spinning of the PVA polymer and the aq. original liquid of the high-polymer electrolyte is then subjected to the freezing treatment and thawing treatment. Further, the fibers are subjected to a neutralization treatment in addition to the above-mentioned treatments. The mechanical strength is enhanced in this way and the response speed is increased.
<P>PROBLEM TO BE SOLVED: To develop a dispersion having excellent dispersion stability, i.e. a dispersion in which an ultraviolet scattering agent is uniformly dispersed in the dispersion stably over a long period when the ultraviolet scattering agent is dispersed in a dispersing agent, and to prepare a cosmetic comprising the dispersion formulated therein and having excellent emulsification stability, or the like.  <P>SOLUTION: The ultraviolet scattering agent coated with an inorganic oxide is formulated with the dispersing agent. Thereby, the dispersion suppressing aggregation of the ultraviolet scattering agent and having excellent dispersion stability is provided. The excellently safe cosmetic having high ultraviolet protective effects, better emulsification stability than that of a conventional product and further an excellent feeling of use is provided by using the ultraviolet scattering agent coated with the inorganic oxide and the dispersing agent or the dispersion.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
EOVIST (gadoxetate disodium) is a paramagnetic contrast agent administered for MRI. EOVIST is provided as a sterile, clear, colorless to pale yellow aqueous solution for intravenous injection.

EOVIST contains the active pharmaceutical ingredient, gadoxetate disodium (Gd‑EOB‑DTPA). The chemical name for gadoxetate disodium is (4S)-4-(4-Ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid, gadolinium complex, disodium salt. Gadoxetate disodium has a molecular weight of 725.72 and an empirical formula of GdC23H28N3O11Na2. The structural formula of gadoxetate disodium in aqueous solution is:

Each mL of EOVIST contains 181.43 mg (0.25 mmol) of gadoxetate disodium with 1.00 mg of caloxetate trisodium, 1.21 mg of trometamol, hydrochloric acid and/or sodium hydroxide (for pH adjustment), and water for injection. EOVIST contains no antimicrobial preservative.

Pertinent physiochemical properties of EOVIST are provided in Table 2.